Christchurch Kidney Research Group, Department of Medicine, School of Medicine and Health Sciences, Otago University, Christchurch, New Zealand.
PLoS One. 2013 Apr 23;8(4):e62691. doi: 10.1371/journal.pone.0062691. Print 2013.
Current consensus definitions of Acute Kidney Injury (AKI) utilise thresholds of change in serum or plasma creatinine and urine output. Biomarkers of renal injury have been validated against these definitions. These biomarkers have also been shown to be independently associated with mortality and need for dialysis. For AKI definitions to include these structural biomarkers, there is a need for an independent outcome against which to judge both markers of functional change and structural markers of injury. We illustrate how sensitivity to need for dialysis and death can be used to link functional and structural (biomarker) based definitions of AKI. We demonstrated the methodology in a representative cohort of critically ill patients, in which an increase of plasma creatinine of >26.4 µmol/L in 48 hours or >50% in 7 days (Functional-AKI) had a sensitivity of 62% for death or dialysis within 30 days. In a development sub-cohort the urinary neutrophil-gelatinase-associated-lipocalin threshold with a 62% sensitivity for death or dialysis was 140 ng/ml (Structural-AKI). Using these thresholds in a validation sub-cohort, the risk of death or dialysis relative to those with no AKI by either definition was, for combined Structural-AKI and Functional-AKI 3.11 (95% Confidence interval: 2.53 to 3.55), for those with Structural-AKI but not Functional-AKI 1.51 (1.26 to 1.62), and for those with Functional-AKI but not Structural-AKI 1.34 (1.16 to 1.42). Linking functional and structural biomarkers via sensitivity for death and dialysis is a viable method by which to define thresholds for novel biomarkers of AKI.
目前,急性肾损伤 (AKI) 的共识定义利用血清或血浆肌酐和尿液输出量的变化阈值。肾损伤的生物标志物已经通过这些定义得到验证。这些生物标志物也被证明与死亡率和透析需求独立相关。为了使 AKI 定义包括这些结构生物标志物,需要一个独立的结果来判断功能变化的标志物和损伤的结构标志物。我们说明了如何使用对透析和死亡的敏感性来将基于功能和结构(生物标志物)的 AKI 定义联系起来。我们在一个具有代表性的危重病患者队列中演示了该方法,其中在 48 小时内血浆肌酐增加 >26.4 µmol/L 或在 7 天内增加 >50%(功能型 AKI)对 30 天内死亡或透析的敏感性为 62%。在一个发展子队列中,尿中性粒细胞明胶酶相关脂质运载蛋白的阈值对死亡或透析的敏感性为 140 ng/ml(结构型 AKI)。在验证子队列中使用这些阈值,相对于两种定义均无 AKI 的患者,死亡或透析的风险为:联合结构型 AKI 和功能型 AKI 为 3.11(95%置信区间:2.53 至 3.55),仅结构型 AKI 为 1.51(1.26 至 1.62),仅功能型 AKI 为 1.34(1.16 至 1.42)。通过对死亡和透析的敏感性来关联功能和结构生物标志物是定义 AKI 新型生物标志物阈值的可行方法。